Ocular Therapeutix Inc (OCUL)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Ocular Therapeutix Inc chart...

About the Company

ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib

CEO

Antony Mattessich

Exchange

NASDAQ

Website

http://www.ocutx.com/

$37M

Total Revenue

274

Employees

$1B

Market Capitalization

-8.57

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $OCUL News

These Analysts Boost Their Forecasts On Ocular Therapeutix After Q4 Results

on MSN ago, source:

Ocular Therapeutix, Inc. (NASDAQ: OCUL) reported worse-than-expected fourth-quarter financial results on Monday. Ocular ...

Ocular Therapeutix Inc Reports Growth Amidst Strategic Shifts

7d ago, source:

Ocular Therapeutix specializes in therapies for diseases and conditions of the eye, leveraging its proprietary hydrogel ...

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results

7d ago, source:

Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial ...

Ocular Therapeutix Inc OCUL

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Decoding 6 Analyst Evaluations For Ocular Therapeutix

5d ago, source:

6 analysts have shared their evaluations of Ocular Therapeutix (NASDAQ:OCUL) during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a ...

ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

6d ago, source: Hosted on MSN

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points on Tuesday. Shares of ACADIA ...

Ocular Therapeutix: Q4 Earnings Snapshot

7d ago, source: The Washington Post

BEDFORD, Mass. — BEDFORD, Mass. — Ocular Therapeutix Inc. (OCUL) on Monday reported a loss of $29.2 million in its fourth quarter. The Bedford, Massachusetts-based company said it had a loss of 35 ...

Ocular Therapeutix(TM) Reports Fourth Quarter and Full Year 2023 Results

7d ago, source: Stockhouse

March 11, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing ...

Ocular Therapeutix: Q4 Earnings Snapshot

8d ago, source: SFGate

BEDFORD, Mass. (AP) — BEDFORD, Mass. (AP) — Ocular Therapeutix Inc. (OCUL) on Monday reported a loss of $29.2 million in its fourth quarter. The Bedford, Massachusetts-based company said it ...

Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Fourth Quarter and Full Year 2023 Results

7d ago, source:

Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy and ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...